Skip to main content

Advertisement

Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry

Fig. 1

Competing risks model resulting from the observable data and including study-specific criteria. Time origin was set to OAD initiation. Any record of insulin use prior to baseline led to exclusion. Study entry (baseline) took place when firstly OAD prescription was recorded (state 0). State 1 represents BOT initiation, state 2 represents stopping OAD medication without BOT initiation being observed. Individuals with neither of these two events within the observational period were right-censored

Back to article page